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Zusammenfassung 
Hintergrund: Das Melanom ist einer der am schnellsten wachsenden Hauttumore. 
Obwohl das Melanom weniger als 5 % der bösartigen Tumore der Haut umfasst, ist 
es verantwortlich für fast 60 % der tödlichen Hautneoplasien. Galektine gehören zur 
Familie der Lektine, die kohlenhydratbindende Proteine sind und die an 
verschiedenen biologischen Vorgängen wie Zellwachstum, Zelladhäsion und 
Metastasierung beteiligt sind. 
Ziele: Das Ziel der vorliegenden Diplomarbeit war es, die Expression  und die 
biologische Aktivität einer Reihe von humanen galektinen in zwei humanen 
Melanom-Zelllinien (MCM1 und DLNxt Zellen) zu untersuchen, die sich in ihrer 
metastatischen Kapazität in vivo unterscheiden. 
Methoden: Diese Arbeit untersuchte (1) die Gen-Expressionsmuster verschiedener 
Galektine mittels RT-qPCR, (2) die galektin-Expression und galektin-
Bindungsstellen durch FACS-Analyse bzw. durch Fluoreszenz-Mikroskopie und (3) 
die Wirkung von Galektinen auf die Zellviabilität, Zelladhäsion und MMP3 und 
TNF-alpha mRNA-Spiegel. 
Resultate: Die Gen-Expressionsanalysen zeigten unterschiedliche Galektin-
Expressionsmuster in den Melanom-Zelllinien. Galektin-1 und -3 waren hoch in 
beiden Zelllinien exprimiert, während Galektin-7, -8 und -9 mittels RT-qPCR kaum 
nachweisbar waren. Das höchste Niveau von Galektin-3-Expression war in MCM1 
Zellen zu sehen, während das höchste Expressionsniveau von Galektin-1 in DLNxt 
Zellen gefunden wurde. Die Unterschiede in der galektin-Expression sowie ihre 
Präsenz auf der Zelloberfläche, im Zytoplasma und in der Kernregion, wurden 
weiters mit Hilfe der Fluoreszenzmikroskopie gezeigt. Galektin-1, -3 und -9 waren 
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diffus im Zytoplasma verteilt, während Galektin-8 eine deutliche vesikuläre 
Akkumulation um die Kerne herum zeigte. Die Präsenz von galektin-Bindungsstellen 
an MCM1 und DLNxt Zellen wurde zudem mittels biotinylierten galektinen 
untersucht. Die Ergebnisse zeigten Unterschiede in der galektin bindung, nicht nur 
zwischen den Zellen, sondern auch zwischen den einzelnen Galektinen. Die 
Anwesenheit von galektin-Bindungsstellen wirft die Frage auf, ob Galektine die 
Zelladhäsion an Kulturflaschen beeinflussen können. Die Ergebnisse zeigten, dass 
die Anwesenheit von Galektin-1 die Zelladhäsion an Kulturflaschen nicht ändert. Im 
Gegensatz dazu erhöhte Galektin-8 die Adhäsion der DLNxt dosisabhängig, während 
die Adhäsion der MCM1-Zellen nicht betroffen war. Darüber hinaus dokumentieren 
RT-qPCR-Daten, dass Galektin-1 die Expression von MMP3 und TNF-alpha in 
DLNxt Zellen reguliert. 
Schlussfolgerungen: Die in dieser Studie vorgestellten Ergebnisse zeigen, dass 
humane Melanomzellen mit unterschiedlichem metastatischem Potenzial, galektine 
auf mRNA- und Protein-Ebene exprimieren. Darüber hinaus wurde gezeigt, dass die 
Zelllinien die jeweiligen galektin-Bindungsstellen exprimieren und dass die 
Anwesenheit von galektinen einen Einfluss auf die mRNA-Expression von MMP3 
und TNF-alpha und auf die Zelladhäsionseigenschaften hat. Zusammenfassend kann 
festgestellt werden, dass diese Studie einen Zusammenhang zwischen der Expression 
von galektinen und galektin-Bindungsstellen und ihrer Beteiligung an Zelladhäsion 
und Tumorverhalten zeigt. 
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Abstract 
Background: Melanoma has been one of the fastest-rising malignancies over the 
past several decades. Although melanoma comprises less than 5 % of malignant skin 
tumors, it is responsible for almost 60 % of lethal skin neoplasia. Galectins belong to 
the family of lectins which are sugar binding proteins that are assumed to be 
involved in cell growth, adhesion and metastasis.  
Aims: The aim of the present study was to investigate the expression and biological 
activity of a set of human galectins in two human melanoma cell lines (MCM1 and 
DLNxt cells), that differ in their metastatic capacity in vivo. 
Methods: This thesis investigated (1) the gene expression pattern of different 
galectins using RT-qPCR, (2) the galectin expression levels and galectin binding-
sites by FACS analysis and by fluorescence microscopy, respectively, and (3) the 
effect of galectins on cell viability, cell adhesion and MMP3 and TNF-alpha mRNA 
levels.  
Results: Gene expression analyses showed a different galectin expression pattern 
among the melanoma cell lines. Galectin-1 and -3 were highly expressed in both cell 
lines, whereas Galectin-7, -8, and -9 were hardly detectable using RT-qPCR. The 
highest level of Galectin-3 expression was seen in MCM1 cells, whereas the highest 
level of Galectin-1 was found in DLNxt cells. The differences in galectin expression 
as well as their presence on the cell surface, in the cytoplasm and around nuclei, 
respectively, have been further demonstrated using fluorescence microscopy. 
Galectin-1, -3, and -9 were diffusely distributed in the cytoplasm, while Galectin-8 
showed a clear vesicular accumulation around the nuclei. MCM1 and DLNxt cells 
were also monitored for accessible galectin-binding sites using biotinylated galectins. 
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Taking unlabeled cells as reference, both cell lines displayed different capacities to 
bind the labeled galectins. The results revealed differences in the galectin-binding, 
not only between the cells but also among the individual galectins. The presence of 
galectin-binding sites prompts the question if galectins could impact the cell 
adhesion to culture flasks. The results showed that the presence of galectin-1 did not 
alter cell adhesion to plastic dishes. In contrast, Galectin-8 increased the DLNxt 
adhesion in a dose-dependent manner, whereas the adhesion of MCM1 cells was not 
affected. Moreover, RT-qPCR data documented that Galectin-1 regulates the 
expression of MMP3 and TNF-alpha in DLNxt cells. 
Conclusion: The results presented in this study demonstrate that human melanoma 
cells with different metastatic potential in vivo express galectins at the mRNA and 
protein level. In addition, we showed that the cell lines express the respective 
galectin binding sites and that the presence of galectins influences the mRNA 
expression levels of MMP3 and TNF-alpha and cell adhesion properties. Taken 
together, this study suggests a relationship between the expression of galectins and 
galectin binding sites and their involvement in cell adhesion and tumor behavior.  
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1 Introduction 
1.1 Skin 
Skin is a vital organ that covers the entire outside of the body, forming a protective 
barrier against pathogens and injuries from the environment. The skin is the body’s 
largest organ weights approximately 10 kg. It protects the organs inside the body 
against infection, heat and ultraviolet light from the sun. It helps to regulate the body 
temperature and to get rid of waste materials through the sweat glands. The skin also 
produces vitamin D and stores water and fat. The skin is composed of three primary 
layers. The layer at the surface is called the Epidermis. Below the epidermis are the 
inner layers: the dermis and the hypodermis [1, 2, 3] 
 
Figure 1: The Structure of the Skin
1 
1.2 The Epidermis 
The epidermis contains the melanocytes, the cells in which melanoma develops, the 
Langerhans cells that are involved in the immune system, the Merkel cells that are 
considered as an adapting mechanoreceptor and sensory nerves.  
                                                 
1 http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic 
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The epidermis layer itself is made up of five sublayers that work together to 
continually rebuild the surface of the skin. 
The Basal Cell Layer (Stratum basale) 
The basal cell layer contains cells called melanocytes. Through a process called 
melanogenesis, these cells produce melanin, which is a pigment found in the skin and 
eyes and which saves the skin from damaging ultraviolet rays, producing a suntan. 
Sometimes melanocytes cluster together and form moles also called nevi. Moles are 
common and are usually not cancerous.  
The Squamos Cell Layer (Stratum spinosum) 
The Squamos cell layer is located above the basal layer. It is the thickest layer of the 
epidermis and participates in the transfer of certain substances into and out from the 
body. The basal cells have been pushed upwards therefore these cells are now called 
squamos cells or keratinocytes. They produce keratin: a protective protein which is 
the main constituent of the structure of the skin, nails and hair. The layer also 
contains the Langerhans cells. 
The Stratum Granulosum and the Stratum Lucidum 
The Stratum Granulosum is superficial to the stratum spinosum, also called grainy 
layer. Stratum Granulosum consist of three to five keratinocytes derived from the 
Stratum Spinosum. Stratum Lucidum covers the Stratum Granulosum. 
The Stratum Corneum 
The Stratum Corneum is the outermost layer of the epidermis, composed of large, 
flat, polyhedral, plate-like envelopes filled with keratin, which is made up of dead 
cells that have migrated up from the Stratum Granulosum. [2, 3, 4] 
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1.3 Malignant Melanoma 
Malignant melanoma is one of the most aggressive malignancies in human. This 
cancer can metastasize rapidly. It develops when melanocytes are damaged, which 
causes these cells to grow uncontrollably. The transformation of melanocytes into 
malignant melanoma involves the interplay between genetic factors, UV exposure 
and the tumor microenvironment [4]. Melanoma begins at the surface of the skin, but 
it can reach the blood and lymphatic vessels, and from there it can spread through the 
body, causing a life-threatening condition. With early detection and proper treatment, 
melanoma has a high cure rate [4, 10, 14]. 
1.3.1 Epidemiology of Melanoma 
Melanoma has been one of the fastest-rising malignancies over the past several 
decades. Even though this cancer type comprises less than 5 % of malignant skin 
tumors, it is responsible for almost 60 % of lethal skin Neoplasia [8]. The annual 
increase in incidence rate of this malignancy varies between populations, but it is 
predominantly in the order of 3–7 % per year in white populations [8, 9] and the 
incidence is 5- to 20-fold lower in populations with darker skin color e.g. Africans, 
East Asians and Hispanics [8, 10]. The highest incidence rate appears to be in 
Queensland, Australia [8, 9, 10]. As reported in the period between 1980 and 1987 
the annual incidence of melanoma was 55.8 per 100,000 inhabitants for men and 
42.9 per 100,000 inhabitants for women. Similar incidence rate were reported also in 
New South Wales, Australia, where the annual incidence of melanoma in the period 
between 1986 and 1988 was 52.5 per 100 000 in men and 42.9 per 100,000 in 
women [10]. The mean annual incidence (age-standardized rate) of invasive 
cutaneous melanoma in Styria, a province of Austria, in the years 2001–2003, was 
24.5 per 100,000 – lifetime risk 1 in 52 [51]. 
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1.3.2 Risk Factors 
The list of risk factors that may have an importance in developing melanoma is very 
large and includes blond or red hair, fair sun-sensitive skin that has the tendency to 
tan poorly or to burn easily, presence of 50 to 100 or more atypical moles, Xerodema 
Pigmentosum, Immune system weakness due to disease or organ transplant or 
medication and genetic factors [2, 14]. The exposure of high penetrating UVB 
radiation leads to DNA lesion such as formation of cyclobutane pyrimidine dimer 
and pyrimidine pyridine photoproducts [4]. The incorrent repair of these products 
leads to a DNA mutation which could be responsible for the tumor progression [4, 
10]. Increased UV-exposure is the main responsible for the three major types of skin 
cancer [4]: 
 Squamous cell skin cancer starts in the squamous cells (thin flat cells found 
on the surface of the skin). 
 Basal cell skin cancer starts in the basal cells (round cells that lie under the 
squamous cells). 
 Melanoma starts in the melanocytes. 
1.3.3 Diagnosis, Staging and Conventional Therapy 
Early detection and treatment are possible because melanoma typically begins at the 
surface of the skin. The majority of persons (more than 85 %) diagnosed at the early 
stages are cured, whereas melanoma diagnosis at later stages of tumor progression is 
associated with a poor prognosis, because the melanoma can be highly malignant and 
metastasize to almost any organ of the body [10]. 
When looking for a melanoma on the skin, it is helpful to apply the ABCD rules [2, 
10]:  
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 A stands for ASYMMETRY; one half unlike the other half 
  B stands for BORDER; irregular, scalloped or poorly defined border 
  C stands for COLOR; varied from one area to another; shades of tan 
 D stands for DIAMETER; melanomas are usually greater than 6 mm  
  (size of a pencil eraser) when diagnosed, but they can be smaller. 
Figure 2: ABCD`s of Melanoma
2 
 
The primary melanoma progresses through two phases which are  
(1) the radial growth phase characterized by horizontal spreading of transformed 
melanocytes within the epidermis and  
(2) the vertical growth phase characterized by invasion of melanoma into the deeper 
dermis [2, 11]. 
Determining how far the cancer has spread is called staging. The staging of 
melanoma is based on the depth of the invasion into the dermis, determined by either 
Clark's method or Breslow's method [2, 10, 12]. 
                                                 
2http://www.melanomafoundation.org/prevention/abcd.htm 
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a) In situ (stage 0) melanomas are noninvasive and have not broken the integrity of 
the epidermal basement membrane (these lesions are not included in melanoma 
statistics). 
b) Stage I (1mm depth) and stage II (1–2.0 mm depth) melanoma is confined to the 
skin, shows an increased thickness and the skin may be intact or ulcerated and is 
treated by surgical excision. 
c) Stage III (2.1–4 mm depth) melanoma has spread to a nearby lymph node and is 
found in increasing amounts within one or more lymph nodes and is treated by 
surgery with or without adjuvant therapy using interferon-α2b [10, 13]. 
d) In stage IV (4 mm depth) melanoma has spread to internal organs, beyond the 
closest lymph nodes to other lymph nodes, or areas of skin far from the original 
tumor. In addition to surgery and radiation therapy, systemic therapy 
(chemotherapy and immunotherapy) is used, but induces complete remissions in 
only a small proportion of patients [13]. The tumor can metastasize only if all 
stages of the cascade occur in the correct order. If only one step gets blocked, it 
can attenuate tumor cell metastases [14]. 
1.3.4 But why does Malignant Melanoma Get Dark?  
The original sources of melanin are the melanoma cells. As already known, melanin 
is the dark pigment of the skin. Melanoma begins first in the melanoma cells and 
exhibits pigmented regions that are darker than the surrounding skin. Beside 
melanoma cells, they are two others melanin-containing cell types that also 
contribute to the dark color: keratinocytes and melanophages [5]. It is quite obvious 
that in the dark regions there is more melanin produced as compared to normal 
melanocytes in adjacent skin. Melanoma melanin appears brown-black consistent 
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with being eumelanin, compared to the gold-red colour of pheomelanin in normal 
skin [6]. Increased melanin synthesis and the production of eumelanin are both sings 
of a normal functioning of MC1-MC1R system – also known as melanocortin-1 
[5, 6]. It plays a main role in melanoma progression. This system leads the activation 
of the proto-oncogene cMet, whose signaling pathway is a key regulator of 
metastasis in melanoma [7]. It has been speculated that the dark melanoma cells 
express an MC1-MC1R system, which is differently activated from that in healthy 
melanocytes, maybe through aberrant glycosylation or other post-translational 
modifications [6]. 
1.3.5 Metastatic Growth 
The metastasis of the tumor is the important step for tumor spreading. Spreading is 
the potential of tumor cells to disperse from the primary site, movement away from 
the original site of disease, intravasation survival in circulation and finally their 
adhesion to the vessel wall and organ homing [14, 15, 16, 17]. Metastasis is a 
complex process and preventing tumor cells from migrating is of medical interest. 
For cells to spread and to be invasive they need to create space by degrading the cell-
cell and the cell-matrix interaction [14, 17]. Melanocytic cells need the initial 
dissociation from the neighbouring keratinocytes followed by migration and dermis 
proliferation and eventually lymphovascular permeabilization [25].  
1.4 The Genetics of Melanoma 
Many genetic and molecular changes are involved in melanoma progression and 
metastasis, and their underlying mechanisms are largely undefined. Involved in 
melanoma invasion are tumor suppressor genes (p16 INK4a/p14ARF, PTEN and 
p53), transcription factors (CREB/ ATF-1, AP-2), oncogenes (BRAF, NRAS), 
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tyrosine kinases (c-kit, PDGF receptors), cell adhesion molecules (E-cadherin, 
β-integrin) and Matrix Metalloproteinases [18]. In 25–50 % of familial melanoma 
worldwide and in approximately 10 % of individuals with multiple primary 
melanoma, a CDKN2A (cyclin-dependent kinase [CDK] inhibitor 2a also p16) 
mutation has been identified. The CDKN2A locus encodes two proteins which 
are involved in growth regulation and apoptosis: namely the p16/INK4a and 
the p14/ARF. The first one inhibits the CDK 4/6 (cyclin-dependent kinase) which in 
cancer cells is constitutively active, leading to an inactivation of uncontrolled 
growth. The second one stabilizes p53, well known as a tumor suppressor and 
proapoptotic protein. Inactivation of p14/ARF leads to abrogation of the p53 
pathway. Loss of both mechanisms allows the damaged cells to proliferate and leads 
to accumulation of further mutations [8, 10, 18, 19]. The most important molecular 
finding over the past decades was the high frequency of NRAS and BRAF mutations 
in melanoma and other cancers. BRAF mutation has been reported in 66 % of 
melanomas. BRAF proteins are serine-threonine kinases and mediators of RAS 
signaling, activates the ERK/MAPK pathway which mediates cell growth and 
proliferation downstream [10, 19, 20]. Mutations of BRAF in exon 15 as well as 
mutations of NRAS in exon 2 have been identified with high increase in nevi, 
cutaneous melanoma and metastasis and are preserved through tumor progression, 
indicating they are the key pathological events [20, 21]. 
1.4.1 Role of Adhesion Molecules in the Progression and Metastasis of 
Melanoma 
Cell Adhesion Molecules (CAMs) are typically transmembrane receptors located on 
the cell surface. Cell surface adhesion molecules play vital roles in numerous cellular 
processes. Some of these including: cell growth, differentiation, embryogenesis, 
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immune cell transmigration and response, and cancer metastasis. Cell Adhesion 
molecules are composed of three domains: an intracellular domain that interacts with 
the cytoskeleton, a transmembrane domain and an extracellular domain that interacts 
with other CAMs of the same kind homophilic binding or with other CAMs or the 
extracellular matrix-heterophilic binding. They can also mediate adhesion between 
two cells of the same type, a process called homotypic adhesion, or different cells 
type heterotypic adhesion. It is known that the homotypic interactions between tumor 
cells play a role in extravasation by supporting cell survival and helping organ 
homing, whereas the heterotypic interactions play a central role in tumor cell 
intravasation and extravasation. They were firstly described on the basis of the tissue 
in which they were initially identified. It is now clear that they are ubiquitous and not 
limited to a single tissue. CAMs have also been characterized as calcium-
independent and calcium-dependent. This classification depends on whether calcium 
is needed for the function or not [14].  
a) Integrins – calcium-independent: The Integrins are heterodimers, composed of an 
alpha and beta subunit, which are both fundamental for proper integrin function. 
The integrins contribute to cell growth by providing a link between cytoskeletal 
structures and the extra-cellular matrix proteins. They participate in both cell-
matrix and cell-cell adhesion in a variety of physiologically important processes 
such as haemostasis and wound healing [22]. The adhesion to the extracellular 
matrix strongly depends on the extracellular pH. The cell-matrix interactions are 
promoted by acidic extracellular pH whereas they are impaired in an alkaline 
environment [23]. In some tumors, increased integrin expression is associated 
with increased malignancy and metastasis formation [24]. Cells that derived from 
a malignant melanoma tender to have an increased level of alpha 2 and 4 integrin 
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subunits. Over expression of the alpha4β1 receptor which mediates the interaction 
between melanoma cells and endothelial cells, may play an important role in 
melanoma metastasis. In this context, recent studies have documented an 
increased expression from alpha4β1 in 40 % of invasive and metastatic 
melanoma, whereas it is not expressed by normal melanocytic cells [22]. 
b) Cadherins – calcium-dependent: The most important members of this family are 
E-cadherins (epithelial), P-cadherins (placental) and N-cadherins (neural). Each 
member was found to regulate cell adhesion of particular cell types and thus was 
thought to be fundamental for the organization of the multicellular organism. The 
cadherins will preferentially bind to other receptors within their subclass-
homotypic binding.
 
However, they also possess a weaker binding affinity for 
members of a different subclass within the same superfamily-heterotypic binding. 
Melanocytic cells are found in normal and healthy skin, as a single cells scatered 
around the keratinocytes. It has been shown that keratinocytes control 
proliferation, differentiation and expression of cell surface molecules on 
melanocytes. If this contact disappears, melanocytic cells proliferate rapidly [25]. 
E-cadherins mediates the adhesion between melanoma cells and keratinocytes 
[26]. A manifest loss of E-cadherin expression during melanoma development 
correlates with a loss of keratinocyte-mediated regulation of melanoma cells. In 
this case melanocytes become free from keratinocytes regulation, resulting in 
increased motility, proliferation and invasive potential of melanoma cells [27]. 
A loss of E-cadherin during progression of melanoma directly correlates with an 
increase expression of N-cadherin [26]. The last one mediates the interactions 
between melanoma cells and vascular endothelial cells as well as the 
communication between melanoma cells and fibroblast through gap-junction, and 
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also facilitates the migration of melanoma cells over dermal fibroblasts. This 
change on the repertoire of cadherins plays a key role in melanoma migration, 
survival and metastases [28]. 
1.5 Glycobiology of Melanoma Metastasis 
1.5.1 Protein Glycosylation of Melanoma 
Glycosylation is the enzymatic process that attaches glycans to proteins, lipids or 
other organic molecules. The carbohydrate side chains modulate the interaction of a 
protein with its environment, influencing its solubility, activity and biologic fate. 
This enzymatic process produces one of the fundamental biopolymers found in cells. 
Glycosylation types are classified according to the identity of the atom of the amino 
acid which binds the carbohydrate chain, namely [16, 29]:  
a) C-linked glycosylation refers to the covalent attachment of a mannose residue to a 
tryptophan residue within an extracellular protein. 
b) N-linked glycosylation is based on the attachment of oligosaccharides to a 
nitrogen atom, usually the N4 of Asparagine side-chain, in the consensus 
sequence Asn-X-Ser/Thr, where X is any residue but a Proline. This process 
occurs on secreted or membrane bound proteins, mainly in eukaryotes and archaea 
– most bacteria do not carry this modification. N-glycosylation begins as a co-
translational event in the endoplasmic reticulum, with additions of 14 sugars chain 
(including 2 N-acetylglucosamines, 9 mannoses and 3 glucoses) to an asparagine 
in the polypeptide chain of the target protein. After removing 3 glucose and 
1 mannose residues, the protein is transferred to the Golgi apparatus where the 
glycans lose a variable number of mannose residues and acquire a more complex 
structure during a process called ‘terminal glycosylation’. 
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There are 3 types of mature N-glycans: 
I. high mannose – those that have escaped terminal glycosylation, 
II. hybrid, 
III. complex – with different combinations of mannose, N-acetylglucosamine, 
N-acetylgalactosamine, fucose and sialic acid residues [29]. 
c) O-linked glycans:  a post-translational event that takes place in the cis-Golgi 
compartment after N-glycosylation and folding of the protein. This is the addition 
of glycans to the hydroxyl group of serine or threonine residues by the enzyme 
UDP-N-acetyl-D-galactosamine: polypeptide N-acetylgalactosa-minyltransferase, 
followed by other carbohydrates such as galactose and sialic acid [16, 29]. 
O-linked glycans play important roles in protein localization and trafficking, 
protein solubility, antigenicity and cell-cell interactions. 
 
Figure 3: Examples of the attachment forms of glycans on a protein [16]
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1.5.2 Glycosylation Contributes to the Tumor Behavior 
The interactions between metastatic tumor and extracellular matrix depend on 
modifications of cell surface glycoprotein’s e.g. integrins and cadherins, respectively 
on the carbohydrate side chain at the cell surface. Both adhesion proteins are heavily 
glycosylated and alterations in their glycosylation may play a central role in giving 
rise to invasive and metastatic potential. For successful tumorigenesis there must be 
changes in cellular adhesivity which facilitate the disruption of normal tissue 
architecture [14]. 
1.5.3 Changes in Cell Surface Glycans Associated with the Progression of 
Human Melanoma? 
The surface of mammalian cells is decorated with complex carbohydrates. Aberrant 
glycosylation accompanies various diseases including cancer [30, 31]. Many studies 
have reported that increased levels of sialylated or fucosylated complex type of 
β-1, 6-N-acetylglucosamine branching is associated with malignant transformation, 
including tumor invasion and metastasis [16, 29]. The enzyme that catalyzes this 
process is β-1, 6-N-acetylglucosaminyltransferase V, a Golgi complex enzyme. The 
appearance of increased enzymatic activity correlates with the metastatic potential 
and tumor progression [30]. This glycan structure is not produced by normal 
melanocytes but is characteristic of invasive and metastatic tumors [32]. The 
expression of β-1, 6-branched oligosaccharide correlates with increased melanin 
production, autophagy and high invasive potential in melanoma cells [33]. This was 
illustrated in experiments where inhibition of β-1, 6-branched oligosaccharide 
production virtually eliminated melanin synthesis and markedly decreased 
chemotactic motility in hybrids [33]. The hybrids were created by fusion in culture 
between mouse melanoma cells and human macrophages. It shows that the 
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metastatic and melanogenic phenotypes in hybrids were dependent on β-1, 
6-branched oligosaccharide [33, 34, 35]. This study shows similarities to dark 
malignant melanoma and suggests the possibility that macrophage fusion with 
melanoma cells is the underlying mechanism [34, 35]. While fusion has been 
demonstrated in animal melanoma, analog proof of fusion in human melanoma still 
awaits analysis at the genetic level [5]. 
1.5.4 Galectins 
Lectins are sugar binding proteins that are able to interpret the specific information 
carried by carbohydrate structures in animal cells. The animal lectins are divided into 
two main groups: C-type (calcium-dependent) and S-type (calcium-independent) 
The most relevant group of C-type lectins is the Selectin family consisting of three 
members called E (endothelial), P (platelet) and L (lymphocytes). The Selectins are 
involved in lymphocyte homing to high endothelial venules and in the initial 
processes of attachment of leukocytes to endothelial cells at sites of inflammation 
[36, 37, 38]. 
S-type lectins, also known as Galectins, consist of beta-galactoside binding lectins 
containing homologous carbohydrate recognition domains (CRDs). Already have 
been 14 soluble galectins members identified, named by consecutive numbering. 
A common function of galectins is to cross-link structures containing 
N-acetyl-lactosamine located at the cell surface and within the extracellular matrix. 
They also possess hemagglutination activity, which is attributable to their bivalent 
carbohydrate binding properties [36, 37]. Galectins bind glycoconjugates of the 
extracellular matrix (ECM) via the CRDs. The galectin Carbohydrate Recognition 
Domain (CRD) consists of ~135 amino acids. Each of CRDs consists of three exons. 
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The amino acid sequence will be encoded by the middle one of these three exons. 
This exon represents four contiguous beta-strands and intervening loops, 
incorporating all amino acides that directly interact with the carbohydrate ligand 
[36, 37, 39]. Galectins-1, -2, -5, -7, -10, and -11 are prototypical galectins, consisting 
of a single CRD, Galectin-3 is also one CRD galectin, but it is unique in that it 
contains unusual tandem repeats of proline- and glycine-rich short stretch. Galectins-
4, -6, -8, -9, and -12 are composed of two different CRDs joined by a linker peptide 
chain known also as tandem-repeat type. These molecules can cross-link 
glycoproteins due to the presence of more than one CRD, whereas the prototypical 
galectins must dimerize in order to cross-link target structures [36, 37]. The amino 
acids identity increases to 80–90 % when comparing only the CRDs. Within one 
mammalian species, the amino acids identity of the CRDs among different galectins 
ranges from approximately 20–40 % [37]. The expression levels of galectins are 
distinct but overlap in mammalian tissues. The localization as well as the expression 
levels are modulated by external stimuli, viral infections, inflammatory agents or 
tumor, whereas the secretion levels increases as a stress response which could be 
inflammation or heat shock. It is a fact that galectins play a key role in many 
pathological states, including autoimmune diseases, allergic reactions, inflammation, 
tumor cell metastasis, atherosclerosis and diabetic complications. Galectins can 
either allow or inhibit cellular adhesion by binding one of the interacting partners 
involved in the adhesion process [37, 40]. The effect on adhesion is dependent on the 
concentration and specificity of the galectin as well as the glycosylation state of the 
receptor to which it binds. They can bind to several adhesion molecules such as 
laminin or fibronectin e.g. Galectin-3 and -8. Diverse integrins serve as receptors for 
many galectins e.g. Galectin-1 and -3. Galectins have the ability to cross-link 
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glycoproteins of different cells or glycoproteins of the cell and the ECM. At high 
galectin concentrations, cell surface glycoproteins on individual cells may become 
cross-linked, which also can result in the loss of adhesive potential [37]. 
1.5.4.1  Galectin-1 Expression Correlates with Melanoma Progression 
Galectin-1 is a homodimeric galectin composed of subunit of approximately 130 
amino acids. Each subunit folds as one compact globular domain [37]. A Galectin-1 
expression and over-expression in tumoric cells is a sign of malignant cells 
progression that could be related to tumor metastases. An interesting observation by 
Yoon et al. revealed that Galectin-1 is more expressed in malignant melanoma than 
in melanocytic nevus and dysplastic nevus. It suggests that Galectin-1 might 
contribute to the tumorigenesis and malignancy of melanocytes [41]. 
1.5.4.2  Galectin-3 Expression in Association with Melanoma Progression 
Galectin-3 belongs to the chimera type of galectins, containing a short NH2- terminal 
domain of 12 amino acids, a collagen-like long sequence and a COOH-terminal 
domain. Galectin-3 has been found on the tumor cell surface and plays a role in 
tumor metastasis [42]. Several in vitro studies have demonstrated that the expression 
of the Galectin-3 correlates with the tumor invasion, metastatic cascade and 
inflammation [42, 43]. Very high serum concentrations have been reported in several 
carcinomas including Melanoma [43]. Vereecken and Heenen suggest two options 
that could explain the correlation of high serum levels of Galetin-3 with melanoma 
progression: The first option is that Galectin-3 could directly facilitate the interaction 
between metastatic cells with vascular endothelium cells and the adhesion of 
melanoma cells to elastin-rich tissues such as skin and lung tissues. The second 
option is that Galectin-3 releases advance inflammation which can be related to 
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tumor pressure in cancer patient. It can be produced by inflammatory cells and save 
them from apoptosis. This anti-apoptotic effect of Galectin-3 gives cells a selective 
survival advantage, which is very important in the vascular compartment, in which 
inflammatory and circulating tumor cells could be found in patients with metastatic 
melanoma. [43] 
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Table 1: Members of the Galectin Family of Mammalian Lectins
4 
                                                 
4 The Emerging Funtionality of Endogenous Lectins:A Primer to the Concept and a Case Study on Galetins including Medical 
Implications 
 
Galectin-1 Many cell types Homodimer; Prototype; 14-
15kDa (one CRD) 
Galectin-2 Gastrointestinal tract Homodimer; Prototype; 14kDa       
(one CRD) 
Galectin-3 Many cell types Monomer with one CRD; 
Chimera type; Pro-, Tyr-, Gly-
rich repeats in N-terminal 
section. 27-36kDa 
Galectin-4 Lung, Liver, Colon, Placenta Monomer; Tandem-repeat 
type; 36kDa (two CRDs 
connected by a link peptide) 
Galectin-5 Reticulocytes; Erythrocytes 
(rat) 
Monomer; Prototype; 17kDa      
(one CRD) 
Galectin-6 Small intestine; Colon Tandem-repeat type with two 
CRDs 
Galectin-7 Keratinocytes; Carcinoma 
cells 
Homodimer; Prototype; 15kDa 
(one CRD) 
Galectin-8 Several tissues; in tumor cell 
lines 
Tandem-repeat type; 34kDa       
(two CRDs) 
Galectin-9 Lung; Liver; Small intestine; 
B-cells 
Tandem-repeat type; 36kDa      
(two CRDs) 
Galectin-10 Lung One CRD-like structure with 
specificity to D-Man;16.5kDa 
Galectin-11 Sheep Gastrointestinal tract One CRD resembling 
prototype galectins; 14kDa 
Galectin-12 Several tissues Tandem-repeat type with two 
CRDs; 35.3kDa 
Galectin-13 Kidney; Bladder; Tumor 
cells 
Homodimer; 16.1kDa; (one 
CRD) 
Galectin-14 Ovine eosinophiles; Lung One CRD resembling 
prototype galectins; 18.2kDa 
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1.6   Aim of the Study 
Recently, a set of functionally different melanoma cell lines was developed at the 
Department of Dermatology at the Medical University Vienna (unpublished data). 
Firstly, one melanoma cell line was established from a metastatic melanoma lesion of 
a single patient. The primer cell line was further cultured and 20 independent cell 
clones have been introduced. Only 8 of them (MCM-1; MCM-1a; MCM-1d; MCM-
1g; MCM-1l; MCM-1k; MCM-1m and MCM-1q) were subcutaneously implanted in 
severe combined immune deficient mice (SCID) and have been tested for their 
tumorigenic potential. 
It was shown that only the original cell pool and two clones (MCM1; MCM1-d; 
MCM-1g) have high transplant efficacy while the rest were not transplantable under 
standard conditions. Tumor associated tissue was stain with LYVE-antibody, and 
only one clone (MCM1-d) shows metastatic potential in one case to regional lymph 
nodes but not to lungs. No LYVE staining or lung metastases were observed with 
any of the clones other than MCM1-d. Cell line MCM1-DLNxt results from 
transplantation of clone MCM1-d, shows high transplant efficacy and complete 
staining with LYVE antibody. All animals had metastases in the regional lymph 
nodes and in the lungs [15]. 
As different galectin members are assumed to be involved in cell growth, adhesion 
and metastasis, the aim of the present study was to investigate the expression and 
biological activity of a set of human galectins in two different cell lines, the original 
cell pool MCM1 with tumorigenic potential but less metastatic spreading, and the 
malignant DLNxt cells. As such, we aimed to determine  
(1) the gene expression pattern of different galectins using RT-qPCR, 
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(2) the galectin expression levels and galectin binding-sites by FACS Analysis and 
by fluorescence microscopy, respectively, and 
(3) the effect of galectins on cell viability and cell adhesion. 
The results of this work might contribute to clarify whether glycobiological aspects 
will affect or correlate with the metastatic cell behavior of the MCM-1 cell model. 
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2 Materials and Methods 
2.1 Materials 
All, the galectin antibodies used for the galectin expression and biotynilated galectins 
used to test the galectin-binding sites and the corresponding galectins used to 
determine the cell adhesion properties and the mRNA expression level of TNF-alpha 
such as MMP3, were kindly provided to us by Prof. Hans-Joachim Gabius, Institute 
of Physiological Chemistry, Faculty of Veterinary Medicine, Ludwig-Maximilians-
University, Germany. All other chemicals were of analytical grade and supplied by 
our laboratory, unless otherwise specified. 
2.2 Cell-culture  
Melanoma cell lines DLNxt and MCM1 were routinely grown as monolayer cultures 
in DMEM (Dulbecco's Modified Eagle's Medium), supplemented with 10 % FCS 
(heat-inactivated Fetal Calf Serum) and Penicillin/Streptomycin (10 ml/l), in a 
humidified atmosphere of 5 % CO2 at 37 °C. 
2.3 Splitting  
The medium was aspirated and the cells were washed once with PBS (Phosphate-
Buffer Saline). 0.25 % Trypsin/EDTA (Ethylenediaminetetraacetic acid) was added 
onto the cell layer and incubated at 37 °C for about 5 minutes. The progress of 
detachment was monitored using the microscope. Cells were resuspended in 
complete medium and were transferred into a new culture flask, containing 10 ml 
fresh medium. 
2.4 RNA Isolation and cDNA Synthesis  
DLNxt cells were seeded at 6 × 10
4
 cells/well into a 12 well plate and cultivated as 
described above. At 90 % confluency, cells were serum-starved by changing the 
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culture medium to 2 % ITS medium (Insulin-Transferrin-Selenium). After 6 hours 
incubation, fresh medium mixed with 10 μg/ml Galectin-1 was added to each well. 
Total RNA isolation and on-column DNase digestion (for DNA degradation) were 
performed using the NucleoSpin RNA II Kit following the manufacture supplied 
protocols. The quantity and integrity of isolated RNA samples were determined 
using the Agilent 2100 Bioanalyzer with Nano RNA chips (Agilent). For Real-time 
PCR experiments only those samples that gave RNA Integrity Numbers of 9.1–10 
and showed no DNA contamination in their histogram were used. Cellular RNA was 
processed into cDNA using the High Capacity cDNA Reverse Transcription Kit. All 
cDNA preparations were diluted at ratio 1:5 with RNase-free water prior to Real-
Time PCR.  
2.4.1 Real-time PCR  
All RT-qPCR reactions were performed in 25 μl reaction mixtures containing 
1 μl cDNA (complementary Deoxyribonucleic acid), 12.5 μl SYBR Green Master 
Mix, primer pairs and nuclease-free water to 25 μl. Thermocycling conditions 
consisted of an initial polymerase activation step at 95 °C for 10 min, followed by 35 
cycles at 95 °C for 30 s, at 55 °C for 1 min, and at 72 °C for 1 min. Afterwards, 
melting curves were generated to confirm a single gene-specific peak and to detect 
primer-dimer formation by heating the samples stepwise from 55 °C to 95 °C while 
continuously monitoring the fluorescence. NTC were included in each run to control 
for contaminations. The crossing point of the amplification curve with the threshold 
represented the cycle threshold (Ct). The reactions were run in duplicate and no-
template as controls were included. Used target genes were MMP3 and TNF-alpha 
and as reference gene was used SDHA (Succinate dehydrogenase complex, subunit 
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A). The results were analyzed using the MxPro real-time QPCR software 
(Stratagene).  
 
A. MMP3  
 
B. TNF alpha  
Figure 4: Melting curves were generated to confirm a single gene-specific peak and to detect 
primer-dimer formation by heating the samples stepwise from 55 °C to 95 °C while continuously 
monitoring the fluorescence. MMP3 (figure 4 A. Second Peak) and TNF alpha (figure 4 B. 
Second Peak) with respect to SDHA (figure 4 A and 1 B. First Peak) used as reference gene.  
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2.5 MTT-Assay 
The assay is based on the reducing of the yellow tetrazolium salt MTT (3-[4, 5- 
dimethylthiazol-2-yl]-2, 5-diphenyltetrazolium bromide) to purple formazan crystals 
in mitochondria of metabolic active cells by dehydrogenase enzymes. The MTT Cell 
Proliferation Assay measures the cell proliferation rate and conversely, when 
metabolic events lead to apoptosis or necrosis, the reduction in cell viability. Cells 
were seeded in 96 well tissue culture plates at a density of 3000 cells per well 
following incubation for 24 hours in a humidified atmosphere at 37 °C. 100 μl 2 % 
ITS medium containing 10 μg/ml, 5 μg/ml, and 0.5 μg/ml of Galectin-1, -1DTT, -3,  
-3T, -8, -9 were added to each well. The plate was then incubated at 37 °C for 
48 hours. After incubation, the medium was removed and 20 μl MTT solution in 
200 μl fresh ITS medium were added into each sample and melanoma DLNxt and 
MCM1 cells were incubated for 4 hours at 37 °C. After incubation, the plate was 
gently mixed by tipping at all four sides. The absorbance was measured by using a 
microplate-reader at 450 nm and 620 nm served as reference wavelength. The 
reference wavelength is used to correct for nonspecific background signals 
introduced by fingerprints or other factors. 
2.6 FACS-Flow Cytometric Analysis  
2.6.1 Galectin Expression in Melanoma Cells  
For flow cytometry, 4 × 10
5
 melanoma DLNxt and MCM1cell line were first washed 
with 500 μl DBPS (Dulbeco’s Phosphate-buffered Saline) and fixed by 4 % 
formalin. Membrane permeabilization was performed using 0.5 % Saponin. After 10 
minutes and after centrifugation, the cells were incubated with 100 μg/ml and 
50 μg/ml of Galectin-3 or Galectin-8-Antibodies for 30 min at 37 °C. Cells were 
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washed with FACS Buffer (DPBS with 1 % BSA, 0.01 % NaN3) and stained with 
anti-rabbit IgG-FITC (1:100, Sigma) for 60 min at room temperature.  
2.6.2 Galectin Binding in Melanoma Cells  
4 × 10
5
 melanoma DLNxt and MCM1cell line were centrifuged for 3 minutes at 
3000 rpm and the cell pellets were washed with 500 μl DPBS with 0.1 % BSA. 
Afterwards, cells were incubated with 50 μg/ml biotinylated Galectin-3 or Galectin-8 
on ice for 30 minutes. The cells were again washed with washing buffer. 
Streptavidin-R-Phycoerythrin (1:40, Sigma) was added and the cells were incubated 
for 30 minutes on ice in the dark. Finally, the cells were fixed with 4 % formalin.  
For checking purposes were used cells that were incubated with Streptavidin-R- 
Phycoerythrin (PE) only or Anti-Rabbit-IgG-FITC as second antibodies.  
Besides the protocol described above we used for fixation 2 % formalin. In addition 
to the use of Saponin, membrane permeabilisation was performed also with Triton X 
in concentrations of 0.1 %, 0.5 %, and 1 % and with methanol for 1 hour at –4 °C. 
We changed the incubation period for the first antibody to 1 hour. Incubated was also 
at 37 °C, on ice or at room temperature. The cells were also incubated with the 
second antibody at room temperature.  
2.7 Fluorescence Microscopy  
2.7.1 Galectin Expression in Melanoma Cell Lines DLNxt and MCM1  
To test Galectin-1, -3, -8, and -9 expression in melanoma cells DLNxt and MCM1, 
5 × 10
5
 cells were cultured on glass cover slips for 2 days. At 90 % confluency, cells 
were washed three times with cold PBS and fixed with methanol at –20 °C for 
20 min. After fixation they were washed again with PBS, and rehydration was 
performed using 1 ml 0.1 % BSA (Bovine-serum Albumin) per well for 60 min at 
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room temperature. Cells were then incubated with Galectin-1, -3, -8, and -9 
antibodies (20 μg/ml) for 2 hours at 37 °C. Following additional washes in 0.1 % 
BSA cells were incubated for 1 hour at 37 °C with FITC (fluorescein isothiocyanate) 
and DAPI (4'-6-diamidino-2-phenylindole). After three washing steps with 0.1 % 
BSA, the cover slips were mounted on microscope slides using a drop of FluorSave 
(Fluorsave™ Reagent, 345789, Calbiochem®, Merck Biosciences) and the staining 
was observed under a fluorescence microscope.  
2.7.2 Galectin Binding in Melanoma Cell Lines DLNxt and MCM1  
To determine the Galectin-1, -3, -3T, -3P, -8, -8N, -9, and -9N binding sites, 5 × 10
5
 
cells were seeded onto glass cover slips and grown for 2 days. At 90 % confluence, 
cells were washed three times with cold PBS and fixed with methanol at –20 °C for 
20 min. After fixation they were washed again with PBS, and rehydration was 
performed using 1 ml 0.1 % BSA per well for 60 min at room temperature. Cells 
were then incubated with labeled galectins (40 μg/ml) for 2 hours at 37 °C. 
Following additional washes in 0.1 % BSA cells were incubated for 1 hour at 37 °C 
with PE and DAPI. After three washing steps with 0.1 % BSA, the cover slips were 
mounted on microscope slides using a drop of FluorSave (Fluorsave™ Reagent, 
345789, Calbiochem®, Merck Biosciences) and the staining was observed under a 
fluorescence microscope.  
2.8 Cell Adhesion Assay 
Adhesion assays not only analyze cell-cell interactions or cell-matrix interactions, 
but also provide information about other cellular functionalities such as receptor-
ligand binding or changes in the intracellular signaling pathways [46]. 3 × 10
4
 cells 
were suspended in 400 μl of complete medium and supplemented with Galectin-1 at 
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concentrations of 5 μg/ml, 20 μg/ml, 100 μg/ml, and Galectin-8 at concentrations of 
200 μg/ml, 250 μg/ml, 300 μg/ml, and 350 μg/ml. Following incubation for 30 min at 
room temperature, the cell suspension was divided into 4 wells of a 96-well plate 
prior to incubation at 37 °C for 2 hours. Afterwards, unattached cells were removed 
by washing gently with 100 μl of PBS and attached cells were fixed by the addition 
of 100 μl of 2 % formalin for 20 min at room temperature. Cells that were not 
washed but directly fixed with 2 % formalin, served as 100 % value. Then, cells were 
washed three times with PBS and stained with 100 μl 0.1 % crystal violet in ethanol 
for 60 min at room temperature. Finally, the cells were washed three times with 
100 μl PBS prior to solubilization of the dye with 100 μl acetic acid and incubation 
in an orbital shaker for 5 min at room temperature (150 rpm). Blanks without cells 
were included to test the background binding of crystal violet to the culture plate. 
The absorbance was measured at 570 nm using a microplate reader (TECAN, 
Austria). In addition, control samples lacking the addition of galectins were included. 
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3 Results 
3.1 The Gene Expression Pattern of Galectin-1, -3, -7, -8, and -9 in 
Melanoma Cell Lines  
The expression levels of Galectin-1, -3, -8, -9 in MCM1, MSM1D, MCM1G, and 
DLNxt, were quantified with respect to reference gene SDHA (Succinate 
dehydrogenase complex, subunit A) using Quantitative Real Time-PCR (RT-qPCR). 
Table 2 shows that Galectin-1 is highly expressed in MCM1D and MCM1G 
followed by DLNxt and MCM1. In comparison to Galectin-1, Galectin-3 is 
significantly less expressed in MCM1D, MCM1G and MCM1 and DLNxt cells. 
Galectin-8 and Galectin-9 are expressed only in a small extent, whereas Galectin-7 
mRNA levels were hardly detectable using RT-qPCR.  
 MCM1 
 
MCM1D 
 
MCM1G 
 
DLNxt 
LGALS1 
 
7.27±0.82 
 
11.06±1.53 
 
10.57±1.03 
 
8.26±1.20 
 
LGALS3 
 
1.08±0.12 
 
3.34±0.55 
 
1.25±0.20 
 
0.61±0.10 
 
LGALS7 
 
0.00006±0.000 
 
0.00006±0.000 
 
0.00008±0.000 
 
0.00014±0.00 
 
LGALS8 
 
0.16±0.02 
 
0.19±0.02 
 
0.20±0.03 
 
0.19±0.03 
 
LGALS9 
 
0.01±0.00 
 
0.018±0.003 
 
0.016±0.005 
 
0.003±0.001 
 
 
Table 2: mRNA levels of Galectin-1, -3, -7, -8 and -9 in MCM1, MCM1D, MCM1G, and DLNxt 
cell lines. The mRNA expression was analyzed using RT-qPCR and quantified with respect to 
SDHA as reference gene (mean±SD) 
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3.2 FACS-Flow cytometric analysis  
In order to determine the galectin expression in DLNxt cells, cells were incubated 
with Antigal-1, -3, and -8 and stained with Anti-Rabbit-IgG-FITC. In order to 
evaluate the presence of binding sites of galectins, cells were incubated with 
biotinylated Galectin-1 and -8 and stained with Streptavidin-R-Phycoerythrin. The 
data were analyzed using flow cytometry. Even though we evaluated all the 
alternatives as described in the methods section, we did not come to any results. 
For this reason we have changed to fluorescence microscope.  
 
Figure 5: As negative controls, the cells were treated in parallel, under identical conditions as 
described in the methods section, except that the primary antibody or both the primary and the 
secondary antibodies were excluded from the diluting solutions. 
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Figure 6: Analysis of galectin expression in DLNxt using Antigal-1, Antigal-3, and Antigal-8 at 
concentration of 50 μg/ml and 100 μg/ml. Fluorescence intensity was determined in the absence 
of the marker, which served as control (scan 1) and in the presence of Antigal-1, -3, and -8 
(scans 2, 3, 4).  
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Figure 7: Analysis of galectin-binding on the cell surface of DLNxt using biotynilated  
Galectin-1 and -8 at concentration of 50 μg/ml. Fluorescence intensity was determined in the 
absence of the marker, which served as control (scan 1) and in the presence of biotynilated 
Galectin-1 and -8 (scans 2, 3, 4). 
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3.3 Fluorescence Microskopy 
3.3.1 Galectin Expression in Melanoma cell Line MCM1  
To confirm the expression of Galectin-1, -3, -8, and -9 by the MCM1 cell line the 
cells were stained with the corresponding galectin antibodies and observed under a 
fluorescence microscope (figure 8 A–B). From a comparison between panel B and 
panel A, it is obvious that Galectin-3 is markedly expressed than Galectin-1 
followed by Galectin-8 expression (panel C). Galectin-1 is predominantly 
expressed in the cytoplasm, whereas Galectin-8 is accumulated in vesicular 
structures around the nuclei. Galectin-9 appears to be expressed to a very low 
extent (D). 
 
Figure 8: Analysis of galectin expression in MCM1 cells by fluorescence microscopy. Fixed and 
permeabilized cells were stained with Antigal-1 (A), Antigal-3 (B), Antigal-8 (C), and Antigal-9 
(D) and with FITC as second antibody. DAPI was used to stain the cell nuclei. 
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3.3.2 Galectin Binding to Melanoma Cell Line MCM1  
In order to determine the binding intensities of Galectin-1, -3, -3T, -3P, -8, -8N, -9, 
and -9N in MCM1cells, permeabilized cells were stained with biotinylated 
galectins and monitored using fluorescence microscopy (figure 9–16). The 
findings show that all used biotinylated galectins specifically stained the MCM1 
cells. The staining was in all of the cases predominantly cytoplasmic. Panel A of 
figures 9–16 shows the cell nuclei stained with DAPI, while panel B presents the 
fluorescence intensities corresponding to galectin binding. Panel C shows the DIC 
picture, and panel D the merged image. From a comparison between figure 9 with 
figure 10, it is obvious that both Galectin-1 and Galectin-3 weakly bind to MCM1 
cells. The binding intensities of Galectin-3 and Galectin-3P (figure 10 and figure 
12) are almost similar, whereas the binding of Galectin-3T (figure11) appears to be 
stronger. It is interestingly to see that the N-domain of Galectin-8N (figure 14), 
which seems to be important for the binding affinity, stained with lower intensity 
the MCM1 cells than the whole sequence of Galectin-8 (figure 13). In contrast, the 
N-domain of Galectin-9N stained intensely than Galectin-9 (figure 16 and figure 
15). Of note, Galectin-9N shows a dot-like background staining which might be 
due to media components attached onto the cover slip during fixation.  
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3.3.2.1 Labeled Galectin-1  
 
Figure 9: Analysis of Galectin-1 binding intensity on MCM1 cells by fluorescence microscopy. 
Fixed and permeabilized cells were stained with biotinylated Galectin-1 and with PE as second 
antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the fluorescence 
intensity of biotinylated Galectin-1. Panel C presents the DIC picture and panel D the merged 
image.  
3.3.2.2 Labeled Galectin-3  
 
Figure 10: Analysis of Galectin-3 binding intensity on MCM1 cells by fluorescence microscopy. 
Fixed and permeabilized cells were stained with biotinylated Galectin-3 and with PE as second 
antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the fluorescence 
intensity of biotinylated Galectin-3. Panel C presents the DIC picture and panel D the merged 
image.  
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3.3.2.3 Labeled Galectin-3T  
 
Figure 11: Analysis of Galectin-3T binding intensity on MCM1 cells by fluorescence 
microscopy. Fixed and permeabilized cells were stained with biotinylated Galectin-3T and with 
PE as second antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the 
fluorescence intensity of biotinylated Galectin-3T. Panel C presents the DIC picture and panel D 
the merged image  
3.3.2.4 Labeled Galectin-3P  
 
Figure 12: Analysis of Galectin-3P binding intensity on MCM1 cells by fluorescence microscopy. 
Fixed and permeabilized cells were stained with biotinylated Galectin-3P and with PE as second 
antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the fluorescence 
intensity of biotinylated Galectin-3P. Panel C presents the DIC picture and panel D the merged 
image. 
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3.3.2.5 Labeled Galectin-8  
 
Figure 13: Analysis of Galectin-8 binding intensity on MCM1 cells by fluorescence microscopy. 
Fixed and permeabilized cells were stained with biotinylated Galectin-8 and with PE as second 
antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the fluorescence 
intensity of biotinylated Galectin-8. Panel C presents the DIC picture and panel D the merged 
image.  
3.3.2.6 Labeled Galectin-8N  
 
Figure 14: Analysis of Galectin-8N binding intensity on MCM1 cells by fluorescence 
microscopy. Fixed and permeabilized cells were stained with biotinylated Galectin-8N and with 
PE as second antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the 
fluorescence intensity of biotinylated Galectin-8N. Panel C presents the DIC picture and panel 
D the merged image.  
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3.3.2.7 Labeled Galectin-9  
 
Figure 15: Analysis of Galectin-9 binding intensity on MCM1 cells by fluorescence microscopy. 
Fixed and permeabilized cells were stained with biotinylated Galectin-9 and with PE as second 
antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the fluorescence 
intensity of biotinylated Galectin-9. Panel C presents the DIC picture and panel D the merged 
image.  
3.3.2.8 Labeled Galectin-9N  
 
Figure 16: Analysis of Galectin-9N binding intensity on MCM1 cells by fluorescence 
microscopy. Fixed and permeabilized cells were stained with biotinylated Galectin-9N and with 
PE as second antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the 
fluorescence intensity of biotinylated Galectin-9N. Panel C presents the DIC picture and panel 
D the merged image.  
 51 
3.3.3 Galectin Expression in Melanoma Cell Line DLNxt  
To determine the expression of Galectin-1, -3, -8, and -9 by the melanoma cell line 
DLNxt, the cells were stained with galectin antibodies and observed under a 
fluorescence microscope (figure 17 A–D). All galectin antibodies that have been 
used stained specifically the DLNxt cells but with different intensity, as shown on 
figure 20 A–D. Panel A shows that Galectin-1 is markedly expressed in comparison 
to Galectin-3 (panel B), followed by Galectin-8 expression (panel C). DLNxt cells 
appear to express Galectin-9 in minor extent (panel D). Galectin-1 is diffusely 
distributed in the cytoplasm, Galectin-3 and -9 exhibited a similar but less 
distribution pattern in the cytoplasm (panel A, B, C), while Galectin-8 shows a clear 
vesicular accumulation around the nuclei.  
 
Figure 17: Analysis of Galectin expression on DLNxt cells by fluorescence microscopy. Fixed 
and permeabilized cells were stained with Anti-gal1 (A), Anti-gal3 (B), Anti-gal8 (C), Anti-gal9 
(D), and with FITC as second antibody. DAPI was used to stain the cell nuclei.  
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3.3.4 Galectin Binding to Melanoma Cell Line DLNxt  
In order to evaluate the presence of binding sites of galectin-1, -3, -3T, -3P, -8, -8N,  
-9, and -9N in DLNxt cells, the cells were stained with biotinylated galectins and 
observed under a fluorescence microscope (figures 18–26). Figure 18 shows that 
staining only with secondary antibody resulted in minor extent of unspecific binding. 
In contrast, figures 18–26 demonstrate that all used galectins specifically stained 
DLNxt cells. Panel A of figures 18–26 shows the cell nuclei stained with DAPI, 
whereas panel B presents the fluorescence intensities of galectin binding. Panel C 
shows the DIC picture, and panel D the merged image. From a comparison between 
figure 19 and 20, it is obvious that galectin-1 binds to a smaller extend to DLNxt 
cells than Galectin-3. The binding of Galectin-3 and -3T (figure 21) appears 
comparable whereas that of Galectin-3P (figure 22) appears less. Interestingly, 
Galectin-3, -3T, and -3P intensively stained the background in a dot-like manner, 
which might be due to media components attached onto the cover slip during 
fixation. Furthermore accumulates Galectin-3T around the nucleus, while Galectin-3 
and -3P show occasionally cytoplasmic staining. Comparison between figure 23 and 
24 makes clear that the whole sequence of Galectin-8 affects the binding, otherwise, 
the N-domain of Galectin-8, which is responsible for the binding on the cell surface, 
stained intensely in addition to a vesicular accumulation around the nuclei. The same 
is observed in case of Galectin-9 and -9N, where the N-domain shows an increased 
binding compared to the whole extent of Galectin-9 (figure 25 and 26). 
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3.3.4.1 Control  
 
Figure 18: Untreated cells were used as control. The cells were stained only with FITC as second 
antibody.  
3.3.4.2 Labeled Galectin-1  
 
Figure 19: Analysis of Galectin-1 binding intensity on MCM1 cells by fluorescence microscopy. 
Fixed and permeabilized cells were stained with biotinylated Galectin-1 and with PE as second 
antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the fluorescence 
intensity of biotinylated Galectin-1. Panel C presents the DIC picture and panel D the merged 
image.  
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3.3.4.3 Labeled Galectin-3  
 
Figure 20: Analysis of Galectin-3 binding intensity on MCM1 cells by fluorescence microscopy. 
Fixed and permeabilized cells were stained with biotinylated Galectin-3 and with PE as second 
antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the fluorescence 
intensity of biotinylated Galectin-3. Panel C presents the DIC picture and panel D the merged 
image.  
3.3.4.4 Labeled Galectin-3T  
 
Figure 21: Analysis of Galectin-3T binding intensity on MCM1 cells by fluorescence 
microscopy. Fixed and permeabilized cells were stained with biotinylated Galectin-3T and with 
PE as second antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the 
fluorescence intensity of biotinylated Galectin-3T. Panel C presents the DIC picture and panel D 
the merged image.  
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3.3.4.5 Labeled Galectin-3P  
 
Figure 22: Analysis of Galectin-3P binding intensity on MCM1 cells by fluorescence microscopy. 
Fixed and permeabilized cells were stained with biotinylated Galectin-3P and with PE as second 
antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the fluorescence 
intensity of biotinylated Galectin-3P. Panel C presents the DIC picture and panel D the merged 
image.  
3.3.4.6 Labeled Galectin-8  
 
Figure 23: Analysis of Galectin-8 binding intensity on MCM1 cells by fluorescence microscopy. 
Fixed and permeabilized cells were stained with biotinylated Galectin-8 and with PE as second 
antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the fluorescence 
intensity of biotinylated Galectin-8. Panel C presents the DIC picture and panel D the merged 
image.  
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3.3.4.7 Labeled Galectin-8N  
 
Figure 24: Analysis of Galectin-8N binding intensity on MCM1 cells by fluorescence 
microscopy. Fixed and permeabilized cells were stained with biotinylated Galectin-8N and with 
PE as second antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the 
fluorescence intensity of biotinylated Galectin-8N. Panel C presents the DIC picture and panel 
D the merged image. 
3.3.4.8 Labeled Galectin-9  
 
Figure 25: Analysis of Galectin-9 binding intensity on MCM1 cells by fluorescence microscopy. 
Fixed and permeabilized cells were stained with biotinylated Galectin-9 and with PE as second 
antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the fluorescence 
intensity of biotinylated Galectin-9. Panel C presents the DIC picture and panel D the merged 
image.  
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3.3.4.9 Labeled Galectin-9N  
 
Figure 26: Analysis of Galectin-9N binding intensity on MCM1 cells by fluorescence 
microscopy. Fixed and permeabilized cells were stained with biotinylated Galectin-9N and with 
PE as second antibody. Panel A shows cell nuclei stained with DAPI, while panel B shows the 
fluorescence intensity of biotinylated Galectin-9N. Panel C presents the DIC picture and panel 
D the merged image.  
 
3.4 Galectin Effect on DLNxt (A) and MCM1 (B) Cell Viability 
In order to determine the cytotoxic effect of Galectin-1, -1DTT, -3, -3T, -8, -9 in 
DLNxt and MCM1 cell line, the MTT cell viability assay was used. Treatment of 
cells for 48 h with 10 μg/ml, 5 μg/ml, 0.5 μg/ml Galectin-1, -1DTT, -3, -3T, -8 and 
Galectin-9, did not show any significant cytotoxicity against the studied cell lines. 
These results (figure 1 A and 1 B) clearly demonstrate that survival of the cells 
was not affected by the presence of galectins. 
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A. DLNxt 
 
B. MCM1 
Figure 27: Galectin effect on DLNxt (A) and MCM1 (B) cell viability. The cells were seeded in 
96-well plates at an initial density of 3 × 10
3
 cells/well, and incubated with Galectin-1, -1DTT, 
-3, -3T, -8, and -9 for 48 h at 37 °C. Cell survival was assessed by MTT assay after 48 h. DLNxt 
and MCM1 cells incubated with medium alone served as controls. The values were normalized 
to untreated controls and represent the mean±SD. 
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3.5 Up-regulation of MMP3 and TNF alpha by Galectin-1 
To evaluate whether Galectin-1 induces the mRNA expression level of MMP3 and 
TNF alpha, cells were treated with 10μg/ml Galectin-1 and analyzed by RT-q PCR. 
As shown in figure 2 A the expression level of MMP3 was only slightly affected by 
Galectin-1, showing a significant increase after 30 min and 60 min treatment. In 
contrast, TNF alpha (figure 2 B) was significantly up-regulated twofold by 
Galectin-1 after 60 min as compared to untreated cells. 
 
 
A. MMP3 
 
B. TNFalpha 
Figure 28: Time-dependent effects of Galectin-1 on MMP3 (figure 28 A) and TNF alpha 
(figure 28 B) mRNA expression in DLNxt cells as determined by RT-q PCR. Cells were 
incubated with Galectin-1 at a concentration of 10 μg/ml and RNA was isolated at different time 
points. Untreated cells served as control. Statistically significant differences are marked with 
asterisks (p< 0.05). 
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3.6 Cell Adhesion Assay 
3.6.1 Effect of Galectin-1 and -8 on Adhesion  
To investigate whether Galectin-1 or Galectin-8 have an influence on MCM1 and 
DLNxt cell adhesion, the cells were incubated with Galectin-1 and Galectin-8 for 
2 hours and observed using a plate reader. When comparing the 100 % attachment 
value and the control, for both cell lines, it was observed a significant reduction in 
cell number detached through one wash step. As reported in figure 29 the adhesion of 
MCM1cells (figure 29 A) did not seem to be affected by Galectin-8, when compared 
to the untreated control cells. In contrast, the treatment with Galectin-8 significantly 
increased the attachment of DLNxt cells in a dose-dependent manner (figure 29 B) in 
relation to untreated control cells. The maximal effect was achieved at concentrations 
of 250 μg/ml and 300 μg/ml. Generally, the adhesion of DLNxt and MCM1 was not 
affected by the presence of Galectin-1 (data not shown). 
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A. MCM1 
 
B. DLNxt 
 
 
 
 
 
 
 
 
Figure 29: Dose-dependent Effect of Galectin-8 on DLNxt and MCM1 cell Adhesion. Cells were 
incubated with Galectin-8 at concentration of 200 μg/ml, 250 μg/ml, 300 μg/ml and 350 μg/ml for 
2 h and observed using a plate reader. Untreated cells served as control. Statistically significant 
differences are marked with asterisks (p< 0.05). 
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4 Discussion 
Malignant melanoma has developed as one of the fastest-growing and most 
aggressive malignancies over the past several decades. Malignant transformation of 
cells is the pathologic consequence of mutations in cellular genetic control 
mechanisms [4]. 
In this study we aimed to investigate the expression and biological activity of 
selected galectins in two functionally different melanoma cell lines. Members of 
galectins are supposed to mediate the cell adhesion, to regulate cell growth, cell 
proliferation, transformation, metastasis, and apoptosis. It has been demonstrated that 
the expression pattern of various galectins is altered in carcinomas [37, 38]. Studies 
have shown higher levels of Galectin-1 in malignant melanoma, which may 
contribute to tumorigenesis and metastasis [41]. Galectin-1 is a laminin binding 
protein that recognizes poly-N-acetyllactosamine chains. Castronovo et al. have 
investigated that Galectin-1 increases the melanoma cell attachment to laminin in 
dose-dependet manner and therefore could be a modulator of invasion and metastasis 
[44]. Bolander et al. in a study performed in patients with metastasizing malignant 
melanoma, have demonstrated a higher expression of Galectin-1 as compared to 
patients with normal tissues [45]. Galectin-3 is a B-galactoside binding protein that is 
expressed in a variety of neoplastic cell types. Overall, it is proposed that Galectin-3 
may serve as a marker of progression in human melanoma. Vereecken and Heenen 
have already reported a high serum concentration of Galectin-3 in melanoma which 
might correlate with the melanoma progression. Furthermore they showed that 
Galectin-3 could be produced by the tumor cells themselves and save them from 
apoptosis [43]. Galectin-3 expression also correlated with the melanoma progression 
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from benign nevi to dysplastic nevi, followed by primary to metastatic melanoma 
[42].   
In the present study we used the RT-qPCR to analyze the expression of Galectin-1,  
-3, -7, -8 and -9 in MCM1 and DLNxt cell lines. Among the cell lines as well as 
between the individual galectins, there were marked differences on the expression 
pattern. In general, the highest level of Galectin-3 expression was seen in MCM1 cell 
line, whereas the highest level of Galectin-1 expression was found in DLNxt cell 
line, followed by MCM1 cell line. The expression levels of galectin-7, -8, and -9 
were hardly detectable using RT-qPCR. The differences in galectin expression as 
well as their presence on the cell surface, in the cytoplasm and around nuclei, 
respectively, have been further demonstrated using fluorescence microscopy. 
Furthermore MCM1 and DLNxt cells were monitored for accessible galectin-binding 
sites using biotinylated galectins. Taking unlabeled cells as reference, both cell lines 
displayed different capacities to bind the labeled galectins. There were differences in 
the galectin-binding, not only between the cells but also among the individual 
galectins. The presence of galectin-binding sites prompted the question if galectins 
could impact the cell adhesion to culture flasks. 
Cell adhesion is a complex process involved in tissue development and diseases. 
Cells that are derived from multicellular organism are able to adhere to extracellular 
matrix proteins or other cells [46].  
In the presented study we investigated how Galectin-1 and -8 may influence the cell 
adhesion of MCM1 and DLNxt cell lines to culture flask in vitro. The results showed 
that the presence of Galectin-1 did not alter cell adhesion to plastic dishes (data not 
shown). In contrast, Galectin-8 increased the DLNxt adhesion in a dose-dependent 
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manner, whereas the adhesion of MCM1 cells was not affected. These findings 
indicate that Galectin-8 over expression can be involved in cellular attachment, 
spreading and migration of human melanoma cells.  
Galectin-8 is one B-galactoside-binding lectin, and it can modulate cell adhesion and 
migration, which is depending on the way how it interacted with the cells. On the one 
way the immobilized Galectin-8 functions as an ECM protein, whereas the soluble 
Galectin-8 blocks the cell adhesion [47]. 
Metastasis is a process that often needs close cooperation between cancer cells and 
inflammatory cells. The process of metastasis can be divided in four major steps 
[48]. One of these steps is cell spreading. For cells to spread, they need to leave their 
original growth site and to intravasate into blood vessels or lymph. This process 
could be promoted by inflammation, through mediator building that increase the 
vascular permeability. TNF alpha is a metastasis-promoting cytokine. It can induce 
up regulation of Integrin expression which is associated with increased malignancy 
of melanoma cells [49]. 
Matrix metalloproteinase’s are involved in the degradation of ECM components in 
both physiological and pathological processes. It enables melanoma cell to progress 
and to metastasize [50].  
In our study we investigated the effect of Galectin-1 on DLNxt cell line regarding the 
gene expression of TNF-alpha and MMP3, using the RT-PCR. The data showed that 
the presence of Galectin-1 increased the expression of TNF-alpha and MMP3. The 
expression of MMP-3 was only slightly affected, whereas the TNF-alpha expression 
was significantly up-regulated. 
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Galectin expression and their binding site in MCM1 and DLNxt are valuable tools 
for further examination between galetins and tumor biologically relevant parameters. 
Overall, our investigation suggests that galectins play a critical role in melanoma 
tumor growth and metastasis, at least in part by mediating melanoma plasticity and 
tumor behavior and could serve as marker for melanoma spreading. 
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5 Conclusion 
The results presented in this study demonstrate that human melanoma cells with 
different metastatic potential in vivo express galectins at the mRNA and protein 
level. In addition, we showed that the cell lines express the respective galectin 
binding sites and that the presence of galectins influences the mRNA expression 
levels of MMP3 and TNF-alpha and cell adhesion properties. Taken together, this 
study suggests a relationship between the expression of galectins and galectin 
binding sites and their involvement in cell adhesion and tumor behavior. 
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